Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2

Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2

SARS-CoV-2 is the viral agent responsible for the pandemic that in the first months of 2020 caused about 400,000 deaths. Among compounds proposed to fight the SARS-CoV-2-related disease (COVID-19), tyrosine kinase inhibitors (TKIs), already effective in Philadelphia-positive acute lymphoblastic leuk...

Full description

Bibliographic Details
Main Authors: Sara Galimberti, Mario Petrini, Claudia Baratè, Federica Ricci, Serena Balducci, Susanna Grassi, Francesca Guerrini, Elena Ciabatti, Sandra Mechelli, Antonello Di Paolo, Chiara Baldini, Laura Baglietto, Lisa Macera, Pietro Giorgio Spezia, Fabrizio Maggi
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-09-01
Series:Frontiers in Oncology
Subjects:
CML
TKIs
imatinib
nilotinib
TTV
immunity
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.01428/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.01428/full

Similar Items